Clinical Trials Below are current clinical trials.83 studies in Digestive Diseases (open studies only). Filter this list of studies by location, status and more. Influence of Diet on Tissue and Body Fluids in Health and Disease Scottsdale/Phoenix, Ariz. This study aims to compare the fatty acid composition of small sample of fat (visceral and subcutaneous) removed at the time of surgery to operative outcomes and the composition calculated from the person’s dietary history and preoperative imaging with MRI/CT scans. This study will also compare the composition of pancreatic fluid collected to that of a sample of fat removed at the time of surgery to drain the collection. Furthermore, we will study the fatty acid composition of drain fluid placed at the time of surgery to that of their fat samples. SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Rochester, Minn. The purpose of this interventional study is to test and compare the effectiveness of two elimination diets—the 1-food elimination diet (1FED, milk only) and the 6-food elimination diet (6FED, milk, egg, wheat, soy, tree nut/peanuts, and fish/shellfish). The study will also test the effectiveness of swallowed glucocorticoid therapy in some of the study participants for whom diet therapy was not effective. A Quality of Life Assessment of Patients with Biliary Obstruction Undergoing Endoscopic or Percutaneous Drainage Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The aim of this study is to compare the quality of life of patients with biliary obstruction who have undergone an endoscopic or percutaneous drainage. The quality of life of patients witll be assessed using the validated "European Quality of Life-5 Dimensions Questionnaire" and the "Intervention-Dependent Questionnaire" which was developed according to current literature as well as the expert opinion of gastroeneterologists. The Olmsted NAFLD Epidemiology Study (TONES) Rochester, Minn. About this study Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and a major public health issue in the US. It is estimated to affect 1 in 4 adults and it is most commonly found in people who are overweight or obese. Because it is a silent disease (without symptoms until end stage) and the lab tests can be normal, it can be missed in early stages. The fat in the liver can lead to inflammation and eventually scar deposition, which can progress to cirrhosis, liver cancer and need for liver transplantation. This study aims to assess how common this disease is in Olmsted County, what markers can identify the disease early to prevent progression to cirrhosis and what other medical problems occur in people with NAFLD in addition to the liver complications. We plan to enroll a large number of adults, assess their liver with state-of-the-art tests available at Mayo Clinic and follow them over several years to monitor for disease progression and other health complications. The ultimate goal of the study is to identify new markers that predict presence of fatty liver and poor health outcomes, in order to improve population health in the community. Participation eligibility Participants will be identified from the Olmsted County population age 18 or older. Inclusion criteria: 1. Adults age 18 years or older 2. Olmsted County residents at the time of study entry Exclusion criteria: 1. Pediatric population (age<18) 2. Unwilling to participate or unable to consent 3. Known liver disease other than NAFLD at the time of survey 4. Pregnant women 5. Alcohol use in excess (14 drinks or more per week for women and 21 drinks or more per week for men) Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1 Scottsdale/Phoenix, Ariz. This study is being done to better understand the relationship between inflammation in your AT, abnormal deposition of fat around your liver and how this affects its appearance and function and ultimately insulin resistance. A Study to Evaluate the Prevalence and Impact of Eating Disorders Among Patients with Inflammatory Bowel Disease Jacksonville, Fla. The purpose of this study is to assess the prevalence of eating disorders; specifically, Avoidant/Restrictive Food Intake Disorder (ARFID) among adult patients in the IBD clinic and compare to the patient population seen in the primary care clinics at Mayo Clinic Florida. A Study to Examine Financial Distress in Patients Undergoing Treatment of Locally-advanced Rectal Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to examine the needs and gap in our understanding of financial burden experienced by rectal cancer patients from a patient perspective to help provide patient centered care and improve psychosocial outcomes of this group. A Study to Evaluate Ramucirumab Plus Trifluridine/Tipiracil to Treat Patients with Previously-treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to compare, in a non-inferiority fashion, the progression-free survival (PFS) in patients with metastatic refractory gastric/Gastroesophageal Junction (GEJ) adenocarcinoma receiving the combination of ramucirumab with TAS-102 vs. paclitaxel and ramucirumab. A Study to Evaluate Encorafenib Plus Cetuximab with/without Chemotherapy to Treat Metastatic Colorectal Cancer Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of care chemotherapy in participants with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). Novel Stomal Occlusion Device in Patients With a Brooke Ileostomy Rochester, Minn. This investigation constitutes an initial evaluation of the stoma occlusion device in humans with a mature permanent Brooke ileostomy. The overall objective of this study is to assess feasibility and initial operating characteristics of a novel stoma occlusion device. The study will recruit 20 patients for placement of the device into the mature Brooke ileostomy and subsequent 2 hour observation period. The device will remain in the ileostomy for up to 2 hours. Pagination Clinical studies PrevPrevious Page Go to page 66 Go to page 77 Go to page 88 Go to page 99 NextNext Page Medical Professionals Digestive Diseases Clinical Trials